Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Autor: Ramos, Isaac Corro, Versteegh, Matthijs M., de Boer, Rudolf A., Koenders, Jolanda M.A., Linssen, Gerard C.M., Meeder, Joan G., Rutten-van Mölken, Maureen P.M.H.
Zdroj: In Value in Health December 2017 20(10):1260-1269
Databáze: ScienceDirect
Externí odkaz: